News
XtalPi Holdings
--
--
0.00%
XtalPi Holdings (SEHK:2228) Advances AI-Driven Cancer Therapy With Regulatory Clearance
Simply Wall St · 22h ago
Assessing XtalPi Holdings (SEHK:2228) Valuation After Recent Surge in Trading Volume and Volatility
Simply Wall St · 2d ago
BRIEF-XtalPi & PharmaEngine Hit Milestone as PRMT5 Inhibitor PEP08 Gets Trial Nod
Reuters · 2d ago
XtalPi Holdings Ltd. and PharmaEngine's Novel PRMT5 Inhibitor, PEP08, Secures Regulatory Approvals for Phase 1 Clinical Trials in Solid Tumors
XtalPi Holdings Ltd. and PharmaEngine have received regulatory approvals for Phase 1 clinical trials of PEP08, a novel PRMT5 inhibitor targeting solid tumors. The approvals were granted by Australia's HREC and Taiwan's TFDA. This milestone represents a significant advancement in their AI drug discovery collaboration and triggered a payment to XtalPi under their partnership agreement.
Reuters · 2d ago
XtalPi Holdings Completes HK$2,629.8 Million Private Placement of New Shares Under General Mandate
XtalPi Holdings Limited completed a private placement of new shares under a general mandate, issuing shares at HK$9.28 per share to at least six placees. The placement represents approximately 6.64% of the company's enlarged issued share capital, generating gross proceeds of HK$2,653.3 million and net proceeds of HK$2,629.8 million. The company intends to use the funds for business development, market expansion, and investment opportunities, with potential short-term investment of unused proceeds.
Reuters · 09/04 09:32
XtalPi Holdings First Half 2025 Earnings: EPS: CN¥0.015 (vs CN¥1.70 loss in 1H 2024)
Simply Wall St · 08/29 23:15
XtalPi Holdings (HKG:2228) Is Using Debt Safely
XtalPi Holdings Limited (HKG:2228) has a strong financial position with CN¥5.02b in net cash, despite increasing debt from CN¥64.9m to CN¥280.9m in a year. The company experienced remarkable 245% revenue growth over 12 months, though it has not yet reported earnings. While currently losing money and experiencing negative free cash flow, its substantial cash reserves provide a buffer, potentially allowing it to fund growth for at least two years. The company's high growth potential is balanced by its current financial risks, but its significant cash position suggests it can manage its debt safely.
Simply Wall St · 08/28 22:54
XTALPI SIGNS MOU WITH DONG-A ST FOR JOINT RESEARCH AND DEVELOPMENT OF IMMUNOLOGY AND INFLAMMATION THERAPIES
Reuters · 08/20 00:00
XTALPI AND DOVETREE ANNOUNCE LANDMARK $6 BILLION AI DRUG DISCOVERY COLLABORATION
Reuters · 08/06 23:57
XTALPI AND PFIZER EXPAND STRATEGIC COLLABORATION TO ADVANCE AI-DRIVEN DRUG DISCOVERY AND MATERIALS SCIENCE SIMULATIONS
Reuters · 06/30 01:23
XTALPI ANNOUNCES STRATEGIC ACQUISITION OF LIVERPOOL CHIROCHEM (LCC), UNLOCKING UNPRECEDENTED POWER IN CHEMICAL SPACE EXPLORATION
Reuters · 06/13 07:00
XtalPi Holdings Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St · 04/11 23:43
An Intrinsic Calculation For XtalPi Holdings Limited (HKG:2228) Suggests It's 24% Undervalued
Simply Wall St · 03/28 01:22
BUZZ-HK's XtalPi jumps on involvement in AI integration project, share sale plan
Shares of XtalPi Holdings jump 9.7% to HK$7.11; set for biggest one-day pct gain since Feb. 10. Company involved in involvement in AI integration project, share sale plan. Set for sale of 342.3 million shares to raise $268.8 million.
Reuters · 02/19 03:30
BUZZ-XtalPi rises after co targets HK$250 million revenue to meet Hong Kong listing threshold
Shares of XtalPi Holdings 2228.HK jump as much as 9.7% to highest level since November 8. Stock on track for biggest one-day pct gain since February 10. Company expects 2024 revenue to reach HK$250 million to meet Hong Kong listing threshold.
Reuters · 02/17 03:01
XtalPi Holdings (HKG:2228) Has Debt But No Earnings; Should You Worry?
XtalPi Holdings Limited (HKG:2228) does carry debt. The company has CN¥64.9m of debt, but has a net cash position of CN¿3.32b. Debt can be a concern for shareholders, but the company has a long history of profitability. Xtal Pi Holdings reported revenue of CN¥197m in the last year. It is using debt in a way that is both safe and conservative.
Simply Wall St · 12/13/2024 00:57
AILUX BIOLOGICS, A DIVISION OF XTALPI, ENTERS INTO A LICENSE AGREEMENT WITH JANSSEN BIOTECH ON BIOLOGICS AI PLATFORM
Reuters · 10/10/2024 12:51
About XtalPi Holdings
XtalPi Holdings Ltd, formerly QuantumPharm Inc, is a holding company primarily engaged in the provision of drug and material science research and development solutions and services in the pharmaceutical and material science industries. The Company mainly operates two businesses. The drug discovery solutions business is engaged in providing modular standalone solutions to or collaborating with a diverse range of biotechnology and pharmaceutical companies and academic institutions for novel drug discovery endeavors. The intelligent automation solutions business is engaged in the provision of solid-state research and development services and automated chemical synthesis services. The Company conducts its business in the domestic and overseas markets.
MoreContact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.